Results of the largest real world dataset in metastatic melanoma via uptake of immune checkpoint inhibitors was presented at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando Florida, February 6-8, 2020. The dataset, comprised of 5465 melanoma patients studied between April 2014 - March 2018 reports that 2322 of the 5465 patients received first-line treatment with immune checkpoint inhibitors (1174 were administered pembrolizumab, 724 ipilimumab, 52 nivolumab, and 372 a combination of both ipilimumab and nivolumab.
To read more about this study, click here.
Source mentioned: Corrie PG, Chao D, Board R, et al. Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018. J Clin Oncol 2020; 38:(suppl 5; abstr 55).
No comments:
Post a Comment